Core Scientific, Inc.
13.10USD
-0.1000 (-0.76%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on CORZ.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 640.3M | 502.4M | 510.7M | 319.0M | 675.6M | 1.1B |
| Q1 | 192.5M | 120.7M | 179.3M | 79.5M | 115.2M | — |
| Q2 | 164.0M | 126.9M | 141.1M | 78.6M | 164.2M | — |
| Q3 | 162.6M | 112.9M | 95.4M | 81.1M | 193.8M | — |
| Q4 | 121.3M* | 141.9M* | 94.9M | 79.8M* | 205.8M | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -6.30 | -.650 | -4.87 | -.880 | -3.79 | .163 |
| Q1 | -1.52 | .000 | .780 | 1.24 | -1.06 | — |
| Q2 | -2.49 | -.020 | -5.05 | -.040 | -3.32 | — |
| Q3 | -1.23 | -.110 | -1.17 | -.450 | -.004 | — |
| Q4 | -1.28* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -.515* |
| -.690 |
| .679* |
| -.029 |
| — |
Debt level and coverage